Abbott Laboratories (ABT) stock had a bullish inflow of $57.05 million worth of trades on uptick and an outflow of $35.34 million in downticks on Friday. The total uptick to downtick ratio stood at 1.61. The net money flow into the stock was $21.7 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $20.53 million. An inflow of $8.18 million block trade was recorded on downticks. $28.7 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 3.51 in favor of the bulls. However, Abbott Laboratories (ABT) stock traded down $0.01 , and reached $43.03, a drop of -0.03% over the previous day. On a weekly basis, the stock is 2.2%, over the previous weeks close.
Abbott Laboratories (ABT) : 11 investment research analysts covering Abbott Laboratories (ABT) have an average price target of $48.36 for the near short term. The highest target price given by the Brokerage Firm to the stock is $50 and the lowest target is $45 for the short term. Analysts expect the variance to be within $1.36 of the average price.
Abbott Laboratories (NYSE:ABT): stock turned positive on Friday. Though the stock opened at $43.05, the bulls momentum made the stock top out at $43.26 level for the day. The stock recorded a low of $42.81 and closed the trading day at $43.17, in the green by 0.30%. The total traded volume for the day was 10,205,059. The stock had closed at $43.04 in the previous days trading.
In a related news, The Securities and Exchange Commission has divulged that Allen Hubert L, Officer (Executive Vice President) of ABBOTT LABORATORIES, had unloaded 3,400 shares at an average price of $37.14 in a transaction dated on June 28, 2016. The total value of the transaction was worth $126,276.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.